Development and Validation of a Seven-Gene Signature for Predicting the Prognosis of Lung Adenocarcinoma

Table 3

Clinical information of LUAD patients in the training set.

	Low risk ()	High risk ()	value
Age
<65	51 (44.0%)	59 (50.4%)	0.392
>65	65 (56.0%)	58 (49.6%)
Event
Yes	17 (14.7%)	40 (34.2%)	<0.001
No	99 (85.3%)	77 (65.8%)
Gender
Female	61 (52.6%)	65 (55.6%)	0.746
Male	55 (47.4%)	52 (44.4%)
T
T1	53 (45.7%)	33 (28.2%)	0.0246
T2	52 (44.8%)	71 (60.7%)
T3	8 (6.9%)	12 (10.3%)
T4	3 (2.6%)	1 (0.9%)
N
N0	85 (73.3%)	56 (47.9%)	<0.001
N1	16 (13.8%)	32 (27.4%)
N2	15 (12.9%)	29 (24.8%)
Tumor stage
Stage I	75 (64.7%)	48 (41.0%)	0.0022
Stage II	22 (19.0%)	35 (29.9%)
Stage III	15 (12.9%)	31 (26.5%)
Stage IV	4 (3.4%)	3 (2.6%)
Smoking
≤40 pack years of smoke	71 (61.2%)	75 (64.1%)	0.748
>40 pack years of smoke	45 (38.8%)	42 (35.9%)